Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.

摘要: // Su-xia Han 1,* , Xia Zhou 2,* Xin Sui Chen-chen He 1 Meng-jiao Cai Jin-lu Ma Yuan-yuan Zhang Cong-ya Chen-xian Armando Varela-Ramirez 3 and Qing Zhu Department of Oncology, The First Affiliated Hospital Xi’an Jiaotong University Medical College, Xi’an, Shaanxi, PR China 2 Biotherapy, Fourth University, Shenyang, Liaoning, Biological Sciences Border Biomedical Research Center, Texas at El Paso, Texas, USA * This authors have contributed equally to this work Correspondence to: Zhu, email: Keywords : pancreatic cancer (PC), dickkopf-1 (DKK1), serum biomarker, diagnosis, prognosis Received April 14, 2015 Accepted May 20, Published June 19, Abstract Purpose: To identify whether Dickkopf-1 (DKK1) could be a potential biomarker for early detection in patients with (PC). Methods: Serum was collected from 140 adenocarcinoma 92 control without adenocarcinoma. Serological levels DKK1 were examined by enzyme-linked immunosorbent assay (ELISA). sensitivity specificity compared carbohydrate antigen 19-9 (CA19-9). A 2-year follow-up monitored evaluate the correlation between overall survival. expression PC tumor tissues also evaluated using immunohistochemistry staining. Results: CA19-9 elevated early-stage cases. These increased advancement clinical stage. There significant difference advanced stages. Receiver operating characteristic curve (ROCC) analysis showed that significantly better than differentiating controls (area under (AUC) 0.919 versus 0.853, respectively), especially distinguishing chronic pancreatitis (CP). correlated its samples. survival rate 24.4% group higher found different lower (33.3%). Conclusion: may novel diagnostic/prognostic PC.